Medeva loses patent battle
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MEDEVA, the drugs group, yesterday lost a High Court battle over rights to its new hepatitis B vaccine, seen as the company's most important product, writes Russell Hotten.
Medeva said it was surprised by the decision and would appeal. The company's shares fell from 125p to 119.5p.
Biogen, a US company, brought the action in the UK alleging that Medeva's Hepa-Gene-3 vaccine infringed its patent. The court's decision contradicts a separate ruling last year by the European Patent Office. Biogen has appealed against the EPO's decision. Medeva also faces action on Hepa-Gene-3 from the Institut Pasteur in Paris.
Medeva bought the vaccine from a Swiss company during its development stage, and took it through the final parts of the approval process. However, it was aware that action from Biogen was possible.
The hepatitis B market is worth about dollars 700m a year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments